Aiming to start afresh under a new name, troubled Mei Pharma Inc. wants to merge with Infinity Pharmaceuticals Inc. in an all-stock transaction that would provide the combined outfit enough cash to fund operations through mid-2025. Specifically, coffers of the newly made firm would contain about $100 million for the advancement of three oncology candidates in a pipeline led by Infinity’s phase II-stage eganelisib for head and neck squamous cell carcinoma.
Radiopharmaceutical company Fusion Pharmaceuticals Inc. is acquiring a phase II actinium-based alpha-emitter radiopharma program for prostate cancer from Radiomedix Inc.
Indicating its continuing strategy to invest in antibody-drug conjugates (ADCs), Astrazeneca plc obtained exclusive global rights to Claudin 18.2 ADC CMG-901 from Keymed Biosciences Inc. and Lepu Biopharma Co. Ltd. in a deal worth up to $1.163 billion.
Carna Biosciences Inc. and Sumitomo Pharma Co. Ltd. have identified dual-specificity tyrosine-(Y)-phosphorylation regulated kinase (DYRK) inhibitors reported to be useful for the treatment of cancer, depression, epilepsy, dementia, psychosis, thyroid and gastrointestinal disorders, among others.
Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. has divulged protein mono-ADP-ribosyltransferase TIPARP (PARP-7; ARTD14) inhibitors reported to be useful for the treatment of cancer.
Hangzhou Healzen Therapeutics Co. Ltd. has synthesized programmed cell death 1 (PDCD1; PD-1; CD279)/PD-1 ligand 1 (PD-L1; CD274) interaction inhibitors reported to be useful for the treatment of cancer, infections, immunological and inflammatory disorders.
Researchers at Cincinnati Children's Hospital Medical Center, Kurome Therapeutics Inc. and the U.S. Department of Health and Human Services have disclosed IL-1 receptor-associated kinase 1 (IRAK-1) and/or IRAK-4 and/or FLT3 (FLK2/STK1) inhibitors reported to be useful for the treatment of cancer, autoimmune and inflammatory disorders.
Medulloblastomas (MBs) are the most common malignant brain tumors in pediatric patients. Among the different types of MBs, those driven by MYC amplification present the worst prognosis. In a recent study published in Nature Communications, scientists from Cincinnati Children's Hospital Medical Center and collaborators investigated the molecular and genetic events triggering MYC amplification and malignant transformation in MBs, which remained previously unclear.
RSS
